Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Advertisement

Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0546769/Cancer-Pain-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Advertisement

Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Cancer Pain Therapeutics market. The report identifies the key trends shaping and driving the global Cancer Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Cancer Pain Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cancer Pain Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Cancer Pain Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cancer Pain Therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in Cancer Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Cancer Pain Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cancer Pain Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Cancer Pain Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Cancer Pain Therapeutics: Introduction 7

2.1 Disease Overview 7

2.2 Etiology and Pathophysiology 9

2.3 Epidemiology 10

2.4 Signs and Symptoms 10

2.5 Diagnosis 11

2.5.1 Commonly Used Pain Scales 11

2.6 Treatment and Management Options 12

2.6.1 Pharmacologic Management of Cancer Pain: 12

2.6.2 Non-Opioid Analgesics for Cancer Pain Management 14

2.6.3 Opioid Drugs for Cancer Pain Management 15

2.6.4 Adjuvant Drugs 16

2.7 GlobalData Pipeline Report Guidance 18

3 Cancer Pain Therapeutics: Market Characterization 19

3.1 Cancer Pain Therapeutics Market Size (2005-2010) – Global 19

3.2 Cancer Pain Therapeutics Market Forecast (2010-2017) – Global 20

3.3 Cancer Pain Therapeutics Market Size (2005-2010) – The US 21

3.4 Cancer Pain Therapeutics Market Forecast (2010-2017) – The US 22

3.5 Cancer Pain Therapeutics Market Size (2005-2010) – France 23

3.6 Cancer Pain Therapeutics Market Forecast (2010-2017) – France 24

3.7 Cancer Pain Therapeutics Market Size (2005-2010) – Germany 25

3.8 Cancer Pain Therapeutics Market Forecast (2010-2017) – Germany 26

3.9 Cancer Pain Therapeutics Market Size (2005-2010) – Italy 27

3.10 Cancer Pain Therapeutics Market Forecast (2010-2017) – Italy 28

3.11 Cancer Pain Therapeutics Market Size (2005-2010) – Spain 29

3.12 Cancer Pain Therapeutics Market Forecast (2010-2017) – Spain 30

3.13 Cancer Pain Therapeutics Market Size (2005-2010) – The UK 31

3.14 Cancer Pain Therapeutics Market Forecast (2010-2017) – The UK 32

3.15 Cancer Pain Therapeutics Market Size (2005-2010) – Japan 33

3.16 Cancer Pain Therapeutics Market Forecast (2010-2017) – Japan 34

3.17 Drivers and Barriers for the Cancer Pain Therapeutics Market 35

3.17.1 Drivers for the Cancer Pain Therapeutics Market 35

3.17.2 Barriers for the Cancer Pain Therapeutics Market 35

3.18 Opportunity and Unmet Need Analysis 36

3.19 Key Takeaway 37

4 Cancer Pain Therapeutics: Competitive Assessment 38

4.1 Overview 38

4.2 Strategic Competitor Assessment 38

4.3 Product Profiles for the Major Marketed Products in the Cancer Pain Therapeutics Market 39

4.3.1 Actiq 39

4.3.2 Abstral 40

4.3.3 Fentora (fentanyl citrate) 41

4.3.4 Onsolis 42

4.3.5 Transtec (Buprenorphine) 43

4.3.6 Pecfent 44

4.4 Key Takeaway 44

5 Cancer Pain Therapeutics: Pipeline Assessment 45

5.1 Overview 45

5.2 Strategic Pipeline Assessment 45

5.2.1 Cancer Pain Therapeutics Pipeline – Pipeline by Phases of Development 45

5.2.2 Cancer Pain Therapeutics – Regulatory Filed Products 46

5.2.3 Cancer Pain Therapeutics – Phase III Pipeline 46

5.2.4 Cancer Pain Therapeutics – Phase II Pipeline 46

5.2.5 Cancer Pain Therapeutics – Phase I Pipeline 47

5.2.6 Cancer Pain Market – Discovery and Pre-Clinical Pipeline 47

5.2.7 Technology Trends Analytic Framework 47

5.3 Cancer Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action 49

5.4 Cancer Pain Therapeutics – Promising Drugs Under Clinical Development 50

5.5 Molecule Profile for Promising Drugs Under Clinical Development 51

5.5.1 Ereska (PMI-150, Intranasal Ketamine) 51

5.5.2 Sativex 51

5.5.3 Tetrodotoxin (Tectin) 52

5.6 Key Takeaway 53

6 Cancer Pain Therapeutics: Clinical Trials Mapping 54

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 54

6.2 Clinical Trials by Phase 55

6.3 Clinical Trials by Trial Status 56

6.4 Prominent Sponsors 57

6.5 Top Companies Participating in Cancer Pain Therapeutics Clinical Trials 59

7 Strategic Assessment 60

7.1 Key Events Impacting the Future Market 60

7.2 Cancer Pain Therapeutics: Implications for Future Market Competition 61

8 Cancer Pain Therapeutics: Future Players 62

8.1 Introduction 62

8.2 Company Profiles 63

8.2.1 Cephalon, Inc. 63

8.2.2 Grunenthal GmbH 66

8.2.3 WEX Pharmaceuticals 68

8.2.4 Meda AB 70

8.2.5 ProStrakan Group plc (ProStrakan) 73

8.2.6 Archimedes Pharma Limited 76

8.2.7 Shionogi & Co., Ltd. 77

8.2.8 Hospira, Inc 81

8.2.9 GW Pharmaceuticals plc 83

8.2.10 Johnson & Johnson 85

8.2.11 Other Companies in the Cancer Pain Therapeutics Market 90

9 Cancer Pain Therapeutics: Licensing and Partnership Deals 92

10 Cancer Pain Therapeutics: Appendix 103

10.1 Market Definitions 103

10.2 Abbreviations 103

10.3 Methodology 104

10.3.1 Coverage 104

10.3.2 Secondary Research 104

10.3.3 Forecasting 105

10.3.4 Primary Research 108

10.3.5 Expert Panel Validation 108

10.4 Contact Us 108

10.5 Disclaimer 108

10.6 Bibliography 109

1.1 List of Tables

Table 1: Acute and Chronic Pain Syndromes 9

Table 2: Occurrence of Cancer Pain in the Different Tumor Types 10

Table 3: Non-Opioid Analgesics 14

Table 4: Opioid Analgesics Used for the Treatment of Cancer Pain 15

Table 5: Adjuvant Analgesics 17

Table 6: Cancer Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19

Table 7: Cancer Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 20

Table 8: Cancer Pain Therapeutics Market, The US, Revenue ($m), 2005–2010 21

Table 9: Cancer Pain Therapeutics Market, The US, Forecasts ($m), 2010–2017 22

Table 10: Cancer Pain Therapeutics Market, France, Revenue ($m), 2005–2010 23

Table 11: Cancer Pain Therapeutics Market, France, Forecasts ($m), 2010–2017 24

Table 12: Cancer Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 25

Table 13: Cancer Pain Therapeutics Market, Germany, Forecasts ($m), 2010–2017 26

Table 14: Cancer Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 27

Table 15: Cancer Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017 28

Table 16: Cancer Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 29

Table 17: Cancer Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017 30

Table 18: Cancer Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 31

Table 19: Cancer Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017 32

Table 20: Cancer Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33

Table 21: Cancer Pain Therapeutics Market, Japan, Forecasts ($m), 2010–2017 34

Table 22: Final dose of Actiq following initial titration in all clinical efficacy and safety studies 39

Table 23: Final dose of Abstral following initial titration in all clinical efficacy and safety studies 40

Table 24: Successful Dose of Fentora Following Initial Titration 41

Table 25: Dose of Onsolis Following Initial Titration 42

Table 26: Cancer Pain Therapeutics – Regulatory Filed Products, 2011 46

Table 27: Cancer Pain Therapeutics – Phase III Pipeline, 2011 46

Table 28: Cancer Pain Therapeutics – Phase II Pipeline, 2011 46

Table 29: Cancer Pain Therapeutics – Phase I Pipeline, 2011 47

Table 30: Cancer Pain Therapeutics – Discovery and Pre-Clinical Pipeline, 2011 47

Table 31: Cancer Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011 50

Table 32: Cancer Pain Therapeutics – Clinical Trials by Country, 2011 54

Table 33: Cancer Pain Therapeutics – Clinical Trials by Phase, 2011 55

Table 34: Cancer Pain Therapeutics – Clinical Trials by Status, 2011 56

Table 35: Cancer Pain Therapeutics – Prominent Sponsors, 2011 58

Table 36: Cancer Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 59

Table 37: Cephalon Inc., Pain Management Pipeline, 2011 64

Table 38: Cephalon Inc., Deals, 2010–2011 65

Table 39: Grunenthal GmbH – Pain Management, Pipeline, 2011 67

Table 40: Grunenthal GmbH – Deals 67

Table 41: WEX Pharmaceuticals, Pain Management Pipeline, 2011 70

Table 42: WEX Pharmaceuticals, Cancer Pain Management Pipeline, 2011 70

Table 43: WEX Pharmaceuticals Inc., Deals , 2010-2011 70

Table 44: Meda AB Inc., Pain Management Pipeline, 2011 71

Table 45: Meda AB, Deals, 2010–2011 72

Table 46: ProStrakan Pain Management Pipeline, 2011 74

Table 47: ProStrakan, Deals, 2010–2011 75

Table 48: Archimedes Pharmaceuticals, Pain Management Pipeline, 2011 76

Table 49: Archimedes Pharmaceuticals, Deals, 2010–2011 76

Table 50: Shionogi Pharmaceuticals, Pain Management Pipeline, 2011 78

Table 51: Shionogi Pharmaceuticals, Cancer Pain Management Pipeline, 2011 78

Table 52: Shionogi, Deals, 2010–2011 79

Table 53: Hospira, Deals, 2010–2011 82

Table 54: GW Pharmaceuticals, Pain Management Pipeline, 2011 84

Table 55: GW Pharmaceuticals, Cancer Pain Management Pipeline, 2011 84

Table 56: GW Pharmaceuticals, Deals, 2010–2011 85

Table 57: Johnson & Johnson Pharmaceuticals, Pain Management Pipeline, 2011 86

Table 58: Johnson & Johnson Pharmaceuticals, Cancer Pain Management Pipeline, 2011 86

Table 59: Johnson & Johnson, Deals, 2010–2011 87

Table 60: Cancer Pain Therapeutics Market – Future Players 90

Table 61: Cancer Pain Therapeutics, Global, Deals 92

1.2 List of Figures

Figure 1: Breakthrough Pain 8

Figure 2: Pain Measurement Scale – Numeric Rating Scale 11

Figure 3: Pain Measurement Scale – Visual Analog Scale 11

Figure 4: Pain Measurement Scale – Faces Rating Scale 12

Figure 5: WHO 3–Step Ladder for Cancer Pain Management 13

Figure 6: Cancer Pain Therapeutics Market, Global, Revenue ($m), 2005–2010 19

Figure 7: Cancer Pain Therapeutics Market, Global, Forecast ($m), 2010–2017 20

Figure 8: Cancer Pain Therapeutics Market, The US, Revenue ($m), 2005–2010 21

Figure 9: Cancer Pain Therapeutics Market, The US, Forecast ($m), 2010–2017 22

Figure 10: Cancer Pain Therapeutics Market, France, Revenue ($m), 2005–2010 23

Figure 11: Cancer Pain Therapeutics Market, France, Forecast ($m), 2010–2017 24

Figure 12: Cancer Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 25

Figure 13: Cancer Pain Therapeutics Market, Germany, Forecast ($m), 2010–2017 26

Figure 14: Cancer Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 27

Figure 15: Cancer Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017 28

Figure 16: Cancer Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 29

Figure 17: Cancer Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017 30

Figure 18: Cancer Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 31

Figure 19: Cancer Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017 32

Figure 20: Cancer Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33

Figure 21: Cancer Pain Therapeutics Market, Japan, Forecast ($m), 2010–2017 34

Figure 22: Opportunity and Unmet Need in the Cancer Pain Therapeutics Market 36

Figure 23: Cancer Pain Therapeutics – Strategic Competitor Assessment, 2010 38

Figure 24: Cancer Pain Therapeutics – Pipeline by Phase of Development, 2011 45

Figure 25: Cancer Pain Therapeutics – Technology Trends Analytics Framework, 2011 48

Figure 26: Cancer Pain Therapeutics – Technology Trends Analytics Framework – Description, 2011 48

Figure 27: Cancer Pain Therapeutics – Pipeline by Mechanism of Action, 2011 49

Figure 28: Cancer Pain Therapeutics – Clinical Trials by Country, 2011 54

Figure 29: Cancer Pain Therapeutics – Clinical Trials by Phase, 2011 55

Figure 30: Cancer Pain Therapeutics – Clinical Trials by Status, 2011 56

Figure 31: Cancer Pain Therapeutics – Overall Sponsors, 2011 57

Figure 32: Cancer Pain Therapeutics – Prominent Sponsors, 2011 58

Figure 33: Cancer Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 59

Figure 34: Cancer Pain Therapeutics Market, Drivers and Restraints, 2011 60

Figure 35: Implications for Future Market Competition in the Cancer Pain Market, 2011 61

Figure 36: Cancer Pain Therapeutics Market – Pipeline by Company, 2011 62

Figure 37: GlobalData Market Forecasting Model 107

Companies Mentioned

Cephalon, Inc.

Grunenthal GmbH

WEX Pharmaceuticals

Meda AB

ProStrakan Group plc (ProStrakan)

Archimedes Pharma Limited

Shionogi & Co., Ltd.

Hospira, Inc

GW Pharmaceuticals plc

Johnson & Johnson

To order this report:

Pathology Industry: Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker